Toronto and Munich-based Wayland Group, formerly MariCann (CSE:WAYL) (OTCQB:MRRCF) agreed to supply Cannamedical Pharma Gmbh, a licensed, privately owned importer and distributor of cannabis in Germany to over 2,200 pharmacies, with a minimum of 9,000 kilograms of EU-GMP certified cannabis flowers over a three-year term.
The companies have completed mandatory quality assurance and control audits and have scheduled the first shipment in December of 2018.
“The decision we made…to move to EU-GMP standards for all production, including cannabis flowers, followed by certification…this year by the German Health Authorities, provides Wayland with the opportunity to move a significant amount of product, in this case 9,000 kilograms to Germany, said Ben Ward, CEO of Wayland.
“We’re proud to be one of six companies worldwide…who exceed EU-GMP standards for dry cannabis flowers. This agreement will provide meaningful revenue and profit to the Company over the next three years as we build a sustainable business,” Ward continued.
“Being able to meet the exponentially growing demand of our European client base strengthens our position as the largest independent and privately-owned cannabis distributor in Germany. Cannamedical will formally introduce its CannaSativa®, CannaIndica® and Cannahybrid® product lines during next week’s German pain congress in Mannheim, Germany,” stated David Henn, CEO of Cannamedical.
Learn more about other exciting cannabis companies in the Cannin Report. Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll help you determine which cannabis companies to invest in.
Source Wayland press release